AUS
NZ
UK
CA
USA
IND
Highlights
- Recce Pharmaceuticals receives ethics approval for Phase 3 clinical trial in Indonesia.
- Company advances towards addressing antibiotic resistance with RECCE 327.
- Indonesian clinical trial aims to combat diabetic foot infections.
Recce Pharmaceuticals Ltd (ASX:RCE) has gained approval from Indonesia’s Human Research Ethics Committee to commence a registrational Phase 3 clinical trial for its synthetic anti-infective, RECCE® 327 (R327) topical gel. This trial, targeted toward treating diabetic foot infections (DFIs), represents a pivotal step in the company’s aim to provide effective treatments against antibiotic-resistant infections, often referred to as 'superbugs.'
The approval signifies an essential development milestone for Recce Pharmaceuticals, as R327 aims to combat severe bacterial infections that have become resistant to conventional antibiotics. With the incidence of antibiotic resistance on the rise globally, Recce’s R327 is designed to address this growing health challenge by offering a novel solution for bacterial infections that have become difficult to manage with standard antibiotics.
The trial in Indonesia will evaluate the safety and efficacy of R327 in treating DFIs, a significant and often serious complication for diabetic patients. According to recent estimates, diabetic foot infections lead to substantial health complications, frequently resulting in hospitalization or, in severe cases, amputation. Recce’s focus on DFIs aligns with its broader goal of addressing high-need areas where current antibiotic options are limited or ineffective.
Edison Investment Research recently adjusted its valuation of Recce Pharmaceuticals, recognizing the promising progress in the company’s clinical development. The advancement of R327, along with ongoing partnerships, has positioned Recce to potentially address significant gaps in infection treatment, especially in areas where antibiotic-resistant bacteria present a critical healthcare concern.
Recce Pharmaceuticals is strategically moving towards commercializing R327, with projections to bring it to market by 2026. According to James Graham, CEO of Recce Pharmaceuticals, the Indonesian trial is an achievement made possible by the company’s collaboration with local partners, who are providing vital support for the clinical program's development and execution.
With this landmark trial, Recce Pharmaceuticals is not only progressing in its clinical objectives but also aligning itself with global efforts to combat the spread of antibiotic-resistant bacteria. The company’s synthetic anti-infective, R327, aims to fill a critical gap in the medical landscape by targeting resistant bacterial strains and providing healthcare professionals with a novel tool in infection management.
Recce’s recent progress underscores the company’s commitment to addressing the “silent pandemic” of antibiotic resistance. As the clinical trial advances, the healthcare sector will be closely watching Recce Pharmaceuticals’ journey, as its R327 program holds the potential to offer a breakthrough in managing infections that have become increasingly difficult to treat.
